Plk1 Polo-Box Domain Ligands via Phosphonate Analog and Basic Amino Acid Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PBD-binding inhibitors for polo-like kinase 1 (Plk1) face challenges such as poor potency in cell-based assays due to low cell membrane penetration and anionic charge, and existing efforts to enhance cellular potencies have not been significantly effective, necessitating the development of novel high-affinity ligands with improved pharmaceutical properties.
Innovation Solution
The development of high-affinity peptide mimetic ligands containing a phospho-threonine analog residue, specifically using the phosphonate analog (2S,3R) 2-amino-3-methyl-4-phosphonobutanoic acid (Pmab) to prevent inactivation by cellular phosphatases, and the creation of multi-valent ligands that bind both the kinase domain and polo-box domain of Plk1, including macrocyclic peptidomimetics with enhanced affinity and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phosphopeptides are used as PBD-binding inhibitors, then binding affinity to polo-box domain is improved, but cell membrane penetration and cellular potency deteriorate due to anionic charge
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of phosphopeptides through N-terminal acylation with basic amino acids (arginine or lysine). This structural modification alters the charge parameters of the molecule, converting the overall anionic charge to a more neutral or positively charged state, thereby improving cell membrane penetration while preserving PBD binding affinity through the intact phospho-Ser/Thr motif
Solution Approach 2:
The invention creates composite structures by combining the phospho-Ser/Thr binding motif with N-terminal basic amino acid residues. This composite design integrates two functional elements: the phospho-residue for specific PBD binding and the basic N-terminus for enhanced cellular uptake, resulting in a hybrid peptide structure that overcomes the limitations of simple phosphopeptides
2Ease of operation
If peptide structure is simplified to improve cellular uptake, then cell membrane penetration is improved, but binding affinity and potency deteriorate
Solution Approach 1:
The patent optimizes peptide parameters by systematically varying the N-terminal acylation groups and phospho-residue positions to find the optimal balance between cellular uptake and binding affinity. This parameter optimization allows identification of peptide sequences with maximal potency that maintain both good cellular penetration and high PBD binding affinity
3Reliability
If phosphopeptides are used as therapeutics, then Plk1 inhibition is achieved, but stability against cellular phosphatases deteriorates
Solution Approach 1:
The patent extracts the essential functional element (phospho-Ser/Thr motif) from the complete phosphopeptide structure and combines it with N-terminal basic amino acid modifications. This extraction approach isolates the critical binding determinant while removing or modifying vulnerable regions, creating a more phosphatase-resistant structure that maintains Plk1 inhibition capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These novel ligands demonstrate improved bioavailability, affinity, and potency in biochemical assays, making them suitable for therapeutic use as anti-cancer agents by effectively inhibiting Plk1 with specificity and stability.
Implementation Method 1
His538 and Lys540 from PB2 are pivotal for electrostatic interactions with the negatively charged phosphate group of phospho-Ser/Thr (p-Ser/Thr) residue
Implementation Method 2
The use of the phosphonate analog, (2S,3R) 2-amino-3-methyl-4-phosphonobutanoic acid (Pmab), prevents inactivation by cellular phosphatases
Data Source
AI summary
The description provides novel compounds that may serve as anticancer therapeutics. The compounds of the description bind to polo-like kinases through the polo-box domain. The peptide derivatives of the description have achieved improved efficacy in biochemical assays against Plk1. Exemplary compounds of the description include macrocyclic peptidomimetics with high affinity and selectivity for polo-like kinases, which may provide the basis for a new genre of anticancer therapeutics. Other exemplary compounds of the description include bi-valent compounds with that bind to polo-like kinases through both kinase domain and polo-box domain simultaneously by incorporating additional moieties that target Plk1 kinase domain, which significantly enhances affinitity relative and may provide the basis for a new genre of anticancer therapeutics. The description also provides methods of use, methods of preparation, compositions, and kits thereof. Further, the description provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.